CXCL10 transcripts were most prominent in patients expressing both SSA and SSB autoantibodies and a focus score ≥ 1, and least detected in non-SS sicca controls showing no autoantibody positivity and a negative focus score. Here, CXCL10 is linked to synovial sarcoma.